Shots:
- Lundbeck and Cradle entered a partnership to leverage AI-powered protein engineering for the discovery and optimization of biotherapeutics, with an initial focus on 2 antibody programs targeting CNS diseases
- Lundbeck will deploy Cradle’s generative AI platform in its first end-to-end AI-guided protein engineering workflow, using iterative feedback from experimental data to discover & optimize higher-quality antibody candidates, and reduce wet-lab testing cycles
- The partnership complements Lundbeck’s recent agreement with the Danish Centre for AI Innovation, providing access to the Gefion AI supercomputer to support large-scale scientific modeling and drug discovery efforts
Ref: PRnewswire| Image: Lundbeck & Cradle | Press Release
Related News: Lundbeck Reports Topline P-IIb (PROCEED) Trial Results on Bocunebart in Migraine Prevention
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
